Public preferences for corporate social responsibility activities in the pharmaceutical industry

Empirical evidence from Korea

Hankil Lee, Sang Yong Kim, Goun Kim, Hye-Young Kang

Research output: Contribution to journalArticle

Abstract

Although corporate social responsibility (CSR) activities are common in the pharmaceutical industry, there is little empirical evidence on consumer responses to CSR practices. We investigated public awareness, preferences, and expectations regarding social contribution of the pharmaceutical industry’s CSR activities, and identified the factors associated with such activities. We conducted an online survey with 1,298 respondents comprising two groups: healthy individuals (546) and patients (752). Most respondents (78%) expressed interest in CSR activities undertaken by pharmaceutical companies. However, they reported a lack of awareness and experience thereof; only 26.9% were aware of and 7.9% had experience with such activities. Among our six CSR activity categories, both survey groups showed the highest preference for the “promoting public health” (healthy group: 6.34/10; patient group: 6.37/10) and “emergency disaster relief support” (6.31 and 6.35) categories. Among sub-categories, activities related to “development of innovative drugs in untreated areas” (6.63 and 6.82) and “support for research on new drug development” (6.59 and 6.84) received the highest scores. The mean expectation score of social contribution of all CSR activities was slightly higher than the mean preference score (6.37 and 6.06, respectively). The patient group exhibited a larger difference between the highest and lowest expectation scores than the healthy group (1.11 and 0.64, respectively). The results of the regression analysis revealed that being a patient, being male, and having positive attitudes toward CSR and its expected effects significantly and positively affected public preferences regarding CSR activities. We can conclude that CSR activities with high public preference might be an effective strategy to improve public awareness of the pharmaceutical industry’s CSR activities. Furthermore, the highest preference for CSR activities relates to new drug development, indicating that our society believes the pharmaceutical industry’s key CSR activity should be to pursue its intrinsic mission: to fulfill unmet medical needs by developing new drugs.

Original languageEnglish
Article numbere0221321
JournalPloS one
Volume14
Issue number8
DOIs
Publication statusPublished - 2019 Jan 1

Fingerprint

corporate social responsibility
Social Responsibility
Drug Industry
Korea
Korean Peninsula
Pharmaceutical Preparations
Industry
new drugs
drugs
pharmaceutical industry
Pharmaceutical Societies
disaster recovery
Public health
Regression analysis
Disasters
research support

All Science Journal Classification (ASJC) codes

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

@article{45927aeb9596426087bd28f6a4d381f5,
title = "Public preferences for corporate social responsibility activities in the pharmaceutical industry: Empirical evidence from Korea",
abstract = "Although corporate social responsibility (CSR) activities are common in the pharmaceutical industry, there is little empirical evidence on consumer responses to CSR practices. We investigated public awareness, preferences, and expectations regarding social contribution of the pharmaceutical industry’s CSR activities, and identified the factors associated with such activities. We conducted an online survey with 1,298 respondents comprising two groups: healthy individuals (546) and patients (752). Most respondents (78{\%}) expressed interest in CSR activities undertaken by pharmaceutical companies. However, they reported a lack of awareness and experience thereof; only 26.9{\%} were aware of and 7.9{\%} had experience with such activities. Among our six CSR activity categories, both survey groups showed the highest preference for the “promoting public health” (healthy group: 6.34/10; patient group: 6.37/10) and “emergency disaster relief support” (6.31 and 6.35) categories. Among sub-categories, activities related to “development of innovative drugs in untreated areas” (6.63 and 6.82) and “support for research on new drug development” (6.59 and 6.84) received the highest scores. The mean expectation score of social contribution of all CSR activities was slightly higher than the mean preference score (6.37 and 6.06, respectively). The patient group exhibited a larger difference between the highest and lowest expectation scores than the healthy group (1.11 and 0.64, respectively). The results of the regression analysis revealed that being a patient, being male, and having positive attitudes toward CSR and its expected effects significantly and positively affected public preferences regarding CSR activities. We can conclude that CSR activities with high public preference might be an effective strategy to improve public awareness of the pharmaceutical industry’s CSR activities. Furthermore, the highest preference for CSR activities relates to new drug development, indicating that our society believes the pharmaceutical industry’s key CSR activity should be to pursue its intrinsic mission: to fulfill unmet medical needs by developing new drugs.",
author = "Hankil Lee and Kim, {Sang Yong} and Goun Kim and Hye-Young Kang",
year = "2019",
month = "1",
day = "1",
doi = "10.1371/journal.pone.0221321",
language = "English",
volume = "14",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "8",

}

Public preferences for corporate social responsibility activities in the pharmaceutical industry : Empirical evidence from Korea. / Lee, Hankil; Kim, Sang Yong; Kim, Goun; Kang, Hye-Young.

In: PloS one, Vol. 14, No. 8, e0221321, 01.01.2019.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Public preferences for corporate social responsibility activities in the pharmaceutical industry

T2 - Empirical evidence from Korea

AU - Lee, Hankil

AU - Kim, Sang Yong

AU - Kim, Goun

AU - Kang, Hye-Young

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Although corporate social responsibility (CSR) activities are common in the pharmaceutical industry, there is little empirical evidence on consumer responses to CSR practices. We investigated public awareness, preferences, and expectations regarding social contribution of the pharmaceutical industry’s CSR activities, and identified the factors associated with such activities. We conducted an online survey with 1,298 respondents comprising two groups: healthy individuals (546) and patients (752). Most respondents (78%) expressed interest in CSR activities undertaken by pharmaceutical companies. However, they reported a lack of awareness and experience thereof; only 26.9% were aware of and 7.9% had experience with such activities. Among our six CSR activity categories, both survey groups showed the highest preference for the “promoting public health” (healthy group: 6.34/10; patient group: 6.37/10) and “emergency disaster relief support” (6.31 and 6.35) categories. Among sub-categories, activities related to “development of innovative drugs in untreated areas” (6.63 and 6.82) and “support for research on new drug development” (6.59 and 6.84) received the highest scores. The mean expectation score of social contribution of all CSR activities was slightly higher than the mean preference score (6.37 and 6.06, respectively). The patient group exhibited a larger difference between the highest and lowest expectation scores than the healthy group (1.11 and 0.64, respectively). The results of the regression analysis revealed that being a patient, being male, and having positive attitudes toward CSR and its expected effects significantly and positively affected public preferences regarding CSR activities. We can conclude that CSR activities with high public preference might be an effective strategy to improve public awareness of the pharmaceutical industry’s CSR activities. Furthermore, the highest preference for CSR activities relates to new drug development, indicating that our society believes the pharmaceutical industry’s key CSR activity should be to pursue its intrinsic mission: to fulfill unmet medical needs by developing new drugs.

AB - Although corporate social responsibility (CSR) activities are common in the pharmaceutical industry, there is little empirical evidence on consumer responses to CSR practices. We investigated public awareness, preferences, and expectations regarding social contribution of the pharmaceutical industry’s CSR activities, and identified the factors associated with such activities. We conducted an online survey with 1,298 respondents comprising two groups: healthy individuals (546) and patients (752). Most respondents (78%) expressed interest in CSR activities undertaken by pharmaceutical companies. However, they reported a lack of awareness and experience thereof; only 26.9% were aware of and 7.9% had experience with such activities. Among our six CSR activity categories, both survey groups showed the highest preference for the “promoting public health” (healthy group: 6.34/10; patient group: 6.37/10) and “emergency disaster relief support” (6.31 and 6.35) categories. Among sub-categories, activities related to “development of innovative drugs in untreated areas” (6.63 and 6.82) and “support for research on new drug development” (6.59 and 6.84) received the highest scores. The mean expectation score of social contribution of all CSR activities was slightly higher than the mean preference score (6.37 and 6.06, respectively). The patient group exhibited a larger difference between the highest and lowest expectation scores than the healthy group (1.11 and 0.64, respectively). The results of the regression analysis revealed that being a patient, being male, and having positive attitudes toward CSR and its expected effects significantly and positively affected public preferences regarding CSR activities. We can conclude that CSR activities with high public preference might be an effective strategy to improve public awareness of the pharmaceutical industry’s CSR activities. Furthermore, the highest preference for CSR activities relates to new drug development, indicating that our society believes the pharmaceutical industry’s key CSR activity should be to pursue its intrinsic mission: to fulfill unmet medical needs by developing new drugs.

UR - http://www.scopus.com/inward/record.url?scp=85071050190&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071050190&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0221321

DO - 10.1371/journal.pone.0221321

M3 - Article

VL - 14

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 8

M1 - e0221321

ER -